Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Citius Oncology Inc 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 USA

www.citiusonc.com P: 908-967-6677

Sector:

Medical

Description:

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. Citius Oncology Inc., formerly known as TenX Keane Acquisition, is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 98,868
Enterprise Value, $K 108,258
Shares Outstanding, K 88,275
Float, K 81,390
% Float 92.20%
Short Interest, K 1,213
Short Float 1.37%
Days to Cover 5.97
Short Volume Ratio 0.58
% of Insider Shareholders 7.80%
% of Institutional Shareholders 70.52%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -24,760 K
Last Quarter Sales, $ 3,940 K
Last Quarter Net Income, $ -5,530 K
EBIT, $ -22,370 K
EBITDA, $ -22,370 K

Growth:

1-Year Return -5.88%
3-Year Return -89.03%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 12/23/25
Next Earnings Date 02/13/26
Earnings Per Share ttm -0.31
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 33.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CTOR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -55.19%
Return-on-Assets % -23.99%
Profit Margin % 0.00%
Debt/Equity 0.26
Price/Sales 21.94
Price/Cash Flow N/A
Price/Book 1.65
Book Value/Share 0.66
Interest Coverage -106.73
60-Month Beta 3.09
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar